---
url: https://www.servicesaustralia.gov.au/leukaemia-chronic-myeloid-leukaemia
title: Leukaemia - chronic myeloid leukaemia - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:04.282Z
source: servicesaustralia.gov.au
---
# Leukaemia - chronic myeloid leukaemia

The PBS subsidises asciminib and ponatinib for patients with chronic myeloid leukaemia (CML).

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with asciminib and ponatinib under the _National Health Act 1953_, section 85 for patients with CML.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing asciminib and ponatinib.

## Treatment specifics

### Ponatinib

To be eligible for initial PBS-subsidised treatment with ponatinib, patients must be treated by a medical practitioner.

To be eligible for continuing PBS-subsidised treatment with ponatinib, patients must be treated by either a:

-   medical practitioner
-   nurse practitioner where patient care is being shared with a medical practitioner and the prescription continues existing therapy with this medicine.

## Authority applications

### Applying for initial treatment

#### Asciminib for patients with T315I mutation

Applications for initial authority approval to prescribe PBS-subsidised asciminib to treat CML can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [chronic myeloid leukaemia - asciminib or ponatinib - initial authority application form](/pb171?context=20)
-   relevant attachments.

#### Asciminib for patients without T315I mutation

Applications for initial authority approval to prescribe PBS-subsidised asciminib to treat CML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

### Applying for continuing treatment

#### Asciminib for patients with T315I mutation

Applications for continuing authority approval to prescribe PBS-subsidised asciminib to treat CML can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [chronic myeloid leukaemia - asciminib or ponatinib - continuing authority application form](/pb084?context=20)
-   relevant attachments.

#### Asciminib for patients without T315I mutation

Continuing PBS-subsidised treatment with asciminib is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

### Ponatinib

#### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised ponatinib to treat CML can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [chronic myeloid leukaemia - asciminib or ponatinib - initial authority application form](/pb171?context=20)
-   relevant attachments.

#### Applying for continuing treatment

Applications for first continuing authority approval to prescribe PBS-subsidised ponatinib to treat CML can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [chronic myeloid leukaemia - asciminib or ponatinib - continuing authority application form](/pb084?context=20)
-   relevant attachments.

After we approve the first continuing application for ponatinib treatment, subsequent continuing applications can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
